Hematuria overview: Difference between revisions
| Line 82: | Line 82: | ||
As the degree of hematuria increases, so does the likelihood of finding clinically significant lesions during evaluation. That is, the difference between the yield of life-threatening lesions in patients with gross versus microscopic hematuria has been found to be highly significant. Specifically, among patients with GH, 50% have been found to have a demonstrable cause, with 20% to 25% found to have a urologic malignancy, most commonly bladder cancer and kidney cancer. Given the increased frequency with which clinically significant findings are associated with GH, the recommended evaluation in this setting is relatively uniform. That is, patients presenting with GH in the absence of antecedent trauma or culture-documented UTI should be evaluated with a urine cytologic examination, cystoscopy, and upper tract imaging, preferably CT urogram. | As the degree of hematuria increases, so does the likelihood of finding clinically significant lesions during evaluation. That is, the difference between the yield of life-threatening lesions in patients with gross versus microscopic hematuria has been found to be highly significant. Specifically, among patients with GH, 50% have been found to have a demonstrable cause, with 20% to 25% found to have a urologic malignancy, most commonly bladder cancer and kidney cancer. Given the increased frequency with which clinically significant findings are associated with GH, the recommended evaluation in this setting is relatively uniform. That is, patients presenting with GH in the absence of antecedent trauma or culture-documented UTI should be evaluated with a urine cytologic examination, cystoscopy, and upper tract imaging, preferably CT urogram. | ||
[[Image:Evaluation of Microscopic Hematuria Algorithm.jpg]] | [[Image:Evaluation of Microscopic Hematuria Algorithm.jpg]] | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
Treatment depends on the cause of the disorder, and the type and severity of symptoms. Controlling high blood pressure is usually the most important part of treatment. | |||
Medicines that may be prescribed include: | |||
* Blood pressure medications to control high blood pressure, most commonly angiotensin-converting enzyme inhibitors and angiotensin receptor blockers | |||
* Corticosteroids | |||
* Medications that suppress the immune system | |||
=== Surgery === | === Surgery === | ||
Surgery for hematuria depends on the underlying etiology. | |||
== Prevention == | == Prevention == | ||
There is no specific preventive methods for either hematuria or microscopic hematuria. | |||
== References == | == References == | ||
Revision as of 06:16, 30 January 2017
|
Hematuria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hematuria overview On the Web |
|
American Roentgen Ray Society Images of Hematuria overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Steven C. Campbell, M.D., Ph.D.Associate Editor(s)-in-Chief: Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [2]
Overview
Hematuria is the presence of blood in the urine and is a common condition in urological practice. It accounts for around 20% of urological referrals and is important, as it can be a cardinal symptom of urological malignancy. Around 40% of patients investigated for hematuria are found to have significant underling pathology, half of whom will have a urological malignancy. Therefore, all patients presenting with a single episode of haematuria require urgent investigation. Haematuria in adults should be regarded as a symptom of urological malignancy until proven otherwise. Microscopic hematuria, or microhematuria (MH), is defined as the presence of red blood cells (RBCs) on microscopic examination of the urine not evident on visual inspection of the urine. The prevalence of MH among healthy participants in screening studies is 6.5% (95% confidence interval [CI] 3.4 to 12.2), with higher rates in studies with a predominance of males, older patients, and smokers.
Definition
Definitions for MH vary considerably and range between 1 to 10 red blood cells per high-power fiel. [1] This difference is due to factors affecting related to sample collection and quantification. One of the the most widely used definition of MH is the presence of three or greater red blood cells per high power-field on a properly collected urinary specimen in the absence of an obvious benign cause (e.g. mild trauma or sexual activity preceding the collection).[2]
Classification
Hematuria may be classified based on its source, visibility, duration and pathophysiology.
| classification by its source | Classification by the visibility | Classification by the duration of hematuria | Classification by Pathophysiology |
|---|---|---|---|
|
|
|
|
Causes
Causes of hematuria can range from benign conditions such as urinary tract infection to serious conditions such as bladder cancer.[3] Extrarenal site is responsible for more than 60% of cases of hematuria. Of these, the most important underlying disease is malignancy. In the primary care population, about 5% of patients with microscopic hematuria will have a urinary tract malignancy, mainly of the bladder or prostate. The most common nonmalignant causes of extrarenal hematuria are infections, such as cystitis, prostatitis, and urethritis.Regarding renal causes of microscopic hematuria, the most common cause of isolated glomerular hematuria (without significant proteinuria) is IgA nephropathy, followed by thin basement membrane disease, hereditary nephritis (Alport syndrome), and mild focal glomerulonephritis of other causes.[4]
Differential Diagnosis
Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin, porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.
Epidemiology and Demographics
Asymptomatic hematuria is common in clinical practice, with a prevalence ranging from 0.18% to 38.7%.[5] Transient microscopic hematuria may occur in 6% to 39% of the population studied, but persistent microscopic hematuria in 3 or more consecutive urinalyses occurs less often, and is seen in 0.5% to 2% of the population under study. In the prevalence of underlying urinary tract disease, there is no clear difference between patients with transient microscopic hematuria and those with persistent microscopic hematuria.[6]
Risk Factors
Common risk factors for urinary tract malignancy in patients with hematuria:[7]
- Age older than 35 years
- Analgesic abuse
- Exposure to chemicals or dyes (benzenes or aromatic amines)
- Male sex
- Past or current smoking
- History of any of the following:
- Chronic indwelling foreign body
- Chronic urinary tract infection
- Exposure to known carcinogenic agents or alkylating chemotherapeutic agents
- Gross hematuria
- Irritative voiding symptoms
- Pelvic irradiation
- Urologic disorder or disease
Natural History, Complications and Prognosis
Natural history, complications and prognosis of hematuria and microscopic hematuria depends on the severity of the disease. Finding the cause is the main factor which determines the prognosis. As hematuria has a vast majority of causes the complications depends on the specific etiology.The rate of malignancy detected among patients evaluated for a single positive urinalysis was 3.6%. Thus the most recent AUA guideline panel has determined that a single positive urinalysis is sufficient to prompt evaluation.[8]
Diagnosis
History and Symptoms
History and symptoms of hematuria depends on the eitology. The history should also include an assessment of associated symptoms, such as gross hematuria, voiding symptoms, or flank pain. Patients' risk factors for known causes of hematuria also should be queried. It is important to know the patient's urologic history, particularly any surgeries or febrile UTIs. It is also critical to ask about the patient's general medical history, to identify potentially contributory diagnoses, such as hypertension, renal insufficiency, bleeding disorders, or sickle cell disease. Current medication use, including anticoagulants and antiplatelet therapies, should be elicited, along with recent coagulation values and any concomitant medications that would potentiate the effects of blood thinners. Family history of nephritis, polycystic kidneys, and rare familial tumor syndromes of the kidney (e.g., von Hippel-Lindau) or urothelium (e.g., Lynch syndrome) also may be informative.[9]
Physical Examination
Physical examination of the patient with MH should be focused on isolating the underlying cause. The physical examination findings will vary depending on the etiology, as follows:[1][2]
- Blood pressure, heart rate, respiration rate, temperature, and consciousness level are important to assess hemodynamic stability, volume status, and possible presence of shock or sepsis as the treatment of hematuria is driven by the underlying pathophysiology and is in large part conservative.
- Presence of hypertension may indicate advanced glomerulopathy.
- Skin and mucosal membrane examination are useful to check for signs of bleeding disorders, such as petechiae, purpura, ecchymoses, and gingival bleeding.
- Jugular venous distention indicates volume overload.
- Flank tenderness;
- Masses in the flank, abdomen, suprapubic area, or urethra
- Enlarged, nodular, tender, or fluctuant prostate.
- Bruising
- Fever
Diagnostic Evaluation
As the degree of hematuria increases, so does the likelihood of finding clinically significant lesions during evaluation. That is, the difference between the yield of life-threatening lesions in patients with gross versus microscopic hematuria has been found to be highly significant. Specifically, among patients with GH, 50% have been found to have a demonstrable cause, with 20% to 25% found to have a urologic malignancy, most commonly bladder cancer and kidney cancer. Given the increased frequency with which clinically significant findings are associated with GH, the recommended evaluation in this setting is relatively uniform. That is, patients presenting with GH in the absence of antecedent trauma or culture-documented UTI should be evaluated with a urine cytologic examination, cystoscopy, and upper tract imaging, preferably CT urogram.
Treatment
Medical Therapy
Treatment depends on the cause of the disorder, and the type and severity of symptoms. Controlling high blood pressure is usually the most important part of treatment.
Medicines that may be prescribed include:
- Blood pressure medications to control high blood pressure, most commonly angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
- Corticosteroids
- Medications that suppress the immune system
Surgery
Surgery for hematuria depends on the underlying etiology.
Prevention
There is no specific preventive methods for either hematuria or microscopic hematuria.
References
- ↑ 1.0 1.1 Cohen RA, Brown RS (2003) Clinical practice. Microscopic hematuria. N Engl J Med 348 (23):2330-8. DOI:10.1056/NEJMcp012694 PMID: 12788998
- ↑ 2.0 2.1 Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ et al. (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 188 (6 Suppl):2473-81. DOI:10.1016/j.juro.2012.09.078 PMID: 23098784
- ↑ Rew, Karl (2010). Primary care urology. Philadelphia, Pa. London: Saunders. ISBN 978-1437724899.
- ↑ Rew, Karl (2010). Primary care urology. Philadelphia, Pa. London: Saunders. ISBN 978-1437724899.
- ↑ Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G et al. (2013) Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 88 (2):129-38. DOI:10.1016/j.mayocp.2012.10.004 PMID: 23312369
- ↑ Rew, Karl (2010). Primary care urology. Philadelphia, Pa. London: Saunders. ISBN 978-1437724899.
- ↑ Sharp VJ, Barnes KT, Erickson BA (2013) Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician 88 (11):747-54. PMID: 24364522
- ↑ Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ et al. (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 188 (6 Suppl):2473-81. DOI:10.1016/j.juro.2012.09.078 PMID: 23098784
- ↑ Wein, Alan (2016). Campbell-Walsh urology. Philadelphia, PA: Elsevier. ISBN 978-1455775675.